HAE

Haemonetics Corporation
$76.19
+1.19 (+1.59%)
Mkt Cap 3.46B
Volume 350,101
52W Range 47.32-87.32
Sector Healthcare
Beta 0.52
EPS (TTM) 2.04
P/E Ratio 37.35
Revenue (TTM) 1.33B
Rev Growth (5Y) +5.1%
EPS Growth (5Y) +5.2%
AlphaVal · Fair Value
What we estimate one share is worth
$53.01
Overvalued strong signal
43.7% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B
Stable Earnings Power
69.3 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue 1.33B 1.36B 1.31B 1.17B 993.20M 870.46M 988.48M 967.58M 903.92M 886.12M 908.83M 910.37M
Net Income 97.31M 167.68M 117.56M 115.40M 43.38M 79.47M 76.53M 55.02M 45.57M (26.27M) (55.62M) 16.90M
EPS 2.05 3.31 2.32 2.27 0.85 1.57 1.51 1.07 0.86 -0.51 -1.09 0.33
Free Cash Flow 260.44M 142.45M 115.45M 162.87M 75.75M 71.77M 109.46M 40.32M 145.55M 83.60M 19.46M 4.96M
FCF / Share 5.52 2.83 2.28 3.21 1.48 1.42 2.16 0.78 2.76 1.62 0.38 0.10
Operating CF 293.22M 181.72M 181.75M 273.06M 172.26M 108.81M 158.22M 159.28M 220.35M 159.74M 121.86M 127.18M
Total Assets 2.40B 2.45B 2.20B 1.93B 1.86B 1.82B 1.27B 1.27B 1.24B 1.24B 1.32B 1.48B
Total Debt 1.22B 1.22B 807.79M 765.89M 780.78M 778.28M 441.81M 350.12M 253.68M 314.65M 408.00M 427.89M
Cash & Equiv 245.44M 306.76M 178.80M 284.47M 259.50M 192.31M 137.31M 169.35M 180.17M 139.56M 115.12M 160.66M
Book Value 796.32M 820.84M 959.96M 818.00M 749.42M 731.67M 587.11M 667.87M 752.43M 739.61M 719.98M 826.12M
Return on Equity 0.12 0.20 0.12 0.14 0.06 0.11 0.13 0.08 0.06 -0.04 -0.08 0.02
HAE News
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Jul 08, 2026 12:05 PM · prnewswire.com
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Jul 03, 2026 10:40 AM · zacks.com
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100
Jun 25, 2026 04:38 PM · gurufocus.com
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Jun 15, 2026 09:59 AM · seekingalpha.com
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Jun 12, 2026 03:00 AM · globenewswire.com
Pharvaris Announces Annual General Meeting of Shareholders
Jun 11, 2026 02:50 AM · globenewswire.com
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Jun 08, 2026 03:18 PM · seekingalpha.com
Haemonetics Updates Financial Reporting Segments
Jun 05, 2026 02:30 AM · prnewswire.com
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 02, 2026 12:05 PM · prnewswire.com
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
May 28, 2026 04:00 AM · gurufocus.com